Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by pSivida Corp. on December 15, 2017. The filing details the results of votes on director elections, equity issuance authorizations, executive compensation, and auditor ratification. Note: The request metadata references "Eyepoint, Inc.," but the filing text explicitly identifies the registrant as pSivida Corp.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Shareholders approved all major proposals presented at the meeting. Key outcomes include:
- Director Elections: All seven nominees (David J. Mazzo, Nancy Lurker, Michael Rogers, Douglas Godshall, James Barry, Jay Duker, and Kristine Peterson) were elected. Non-votes were significant, totaling 16,673,053 shares for each nominee.
- Equity Issuance: Shareholders ratified the issuance of 5,900,000 shares of Common Stock to refresh capacity under ASX Listing Rule 7.1 and approved the issuance of equity securities up to an additional 10% of issued capital over 12 months under ASX Listing Rule 7.1A.
- Compensation: Grants of stock options, restricted stock units, and performance stock units to the CEO and non-executive directors were approved. The 2017 executive compensation was approved on an advisory basis.
- Auditor: The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2018 was ratified with overwhelming support (29,450,523 For vs. 1,431,961 Against).
Guidance, Outlook, and Risks
The filing text does not contain management commentary on future guidance, outlook, specific risks, contingencies, or unusual items. The document serves strictly as a record of the shareholder vote results.
Investor Verification Checklist
- Verify the distinction between the registrant name in the filing (pSivida Corp.) and the metadata request (Eyepoint, Inc.).
- Review the definitive proxy statement filed on November 13, 2017, for detailed terms of the equity grants and compensation packages approved.
- Confirm the impact of the approved 10% equity issuance capacity on existing shareholder dilution.
- Check subsequent filings for the actual issuance of the 5,900,000 shares ratified in this report.